Whole Blood EDTA & PBMC cells
After the launch of our Biopred panel this year, Firalis is proud to announce the validation of new matrices during this Summer.
Recently, Firalis Group has developed a mRNA targeted gene sequencing panel, allowing to quantify 2155 mRNAs in whole blood from PAXgene RNA tubes. This tool is intended for the investigation and identification of biomarker candidates for the support of personalized therapy and drug development research in the area of inflammatory-autoimmune disorders. The quantification of mRNAs is performed using the unique targeted sequencing technology that works without RNA extraction from any matrices and now validated for whole blood EDTA and PBMCs.
Reproducibility Mean R > 0.99 and 1340 over 40 CPM on WB EDTA
« Firalis provide all the platforms and skills needed to analyse the Biopred panel under the best quality environment: samples reception, storage in our Biobank, traceability of handling an carrying out the entire process on site in a certified facility. We control the entire value chain to offer you first-class results on your patient cohort or mactrices. Our team of bioinformaticians and statisticians will be happy to analyze your results in order to give the best interpretations for your study ». said Eric Schordan, Head of Molecular Diagnostics at Firalis.
The distribution of PBMCs is very homogeneous at the panel level and their detection level is close to Paxgene data.
|Matrix||Minimum sample requirements|
|Whole blood (EDTA)||1 slide 5 um|
|Extracted RNA||>20 ng|
|PMBCs/ Cell line||from 5000 cells|
|Serum||study on going|
Certification Propel Illumina on Next -Generation Sequencing platform
Certification HTG - European reference lab and qualified service provider
Contact us now to launch your pilot study !
To get further information on the Biopred panel and its benefits,